Stryker Corp (SYK) · Oct 29, 2026 · Earnings
Miss — Adjusted EPS $3.52 vs ~$3.55 consensus
Stryker’s Q3 earnings missed consensus, and the medical-device maker cut its 2026 guidance despite solid organic growth and margin expansion.
Stryker is rebuilding momentum across its MedSurg, Neurotechnology and Orthopaedics franchises after the 2026 cyber incident and while absorbing portfolio changes and acquisition-related complexity. The quarter showed healthy underlying demand, but not enough to meet the market’s already-reduced bar.
The quarter missed consensus on both sales and adjusted earnings. Revenue reached $6.52 billion versus a published consensus of roughly $6.62 billion, while adjusted diluted EPS was $3.52 versus about $3.55. The filing itself says performance “did fall short of our expectations.”
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net sales (Consolidated Statements of Earnings) | $6.52B (+7.7%) | $6.06B | $6.62B |
| Organic sales growth (Sales Growth Analysis) | 7.7% | — | 9.2% implied |
| Adjusted diluted EPS (Non-GAAP Reconciliation) | $3.52 (+10.3%) | $3.19 | $3.55 |
| Adjusted operating margin (Non-GAAP Reconciliation) | 26.2% | 25.6% | — |
The core franchise is still growing, but the mix is uneven. MedSurg and Neurotechnology grew organic sales 9.1%, while Orthopaedics grew 5.9%; within Orthopaedics, hips declined 1.0% and knees rose only 1.1%, partly offset by 15.8% growth in Ortho Tech. The filing says consolidated organic growth was “primarily driven by increased unit volume.”
Margin execution was better than the headline earnings miss suggests. Adjusted operating margin expanded to 26.2% from 25.6%, and adjusted EPS still grew 10.3%. But that improvement was not enough to overcome sales running below expectations, while reported earnings were hit by $293 million of goodwill impairment and $153 million of structural-optimization charges.
The bigger change is the reset to full-year expectations. Stryker now expects 6.5%–7.0% organic sales growth and $14.80–$14.90 of adjusted EPS, down from the prior 8.3%–9.3% organic-growth target and $14.95–$15.10 EPS outlook. That turns a quarter with decent operational progress into a broader credibility setback for the 2026 plan.
The new $3 billion buyback authorization is supportive but secondary. It adds capital-return capacity after $1 billion of repurchases during the first nine months, but it does not repair the shortfall in operating expectations.
Bottom line: Stryker’s underlying business remains healthy, especially in MedSurg and Neurotechnology, but Q3 missed a lowered bar and the company cut its full-year targets. The filing weakens the near-term growth story more than it strengthens the margin story.
Q3 earnings call, October 29
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!